IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 24/04/2020 - Press release

    Biomolecules from olive oil may have beneficial effects on blood vessel health

    Up to now, it was not known what happened in the human body after maslinic acid and oleanolic acid were consumed in diet-compatible quantities, in other words, what happened from the moment they were ingested until their total elimination from the body, what is referred to as pharmacokinetics. Furthermore, information on the biological activity of these biomolecules in the human body is very scarce in the scientific literature.  Using a method for determining oleanolic and maslinic acids in plasma developed by the Integrated Pharmacology and Systems Neuroscience Research Group at the Hospital del Mar Medical Research Institute (IMIM), and the Barcelona Mar Health Park Consortium node of the Physiopathology of Obesity and Nutrition (CIBERobn) network, as part of the NUTRAOLEUM research project, a clinical trial on humans has evaluated the pharmacokinetics of these two triterpenic acids from the olive tree after the ingestion of olive oils enriched in these biomolecules at two different concentrations. In addition, the effect of these triterpenic acids on endothelial function has also been studied, revealing that they contribute to preserving blood vessel health and preventing arteriosclerosis.

    Més informació "Biomolecules from olive oil may have beneficial effects on blood vessel health"

  • Institutional news

    The IMIM becomes part of the European Consortium EATRIS to promote translational medicine

    The IMIM Clinical Metabolomics Platform led by Dr. Oscar J. Pozo, from the IMIM Integrated Pharmacology and Systems Neuroscience Research Group, has become part of the EATRIS consortium, the European infrastructure for translational medicine, as part of the biomarker platform. This means that the IMIM is now part of a consortium comprising more than 80 prestigious European institutes that is aiming to establish synergies between healthcare researchers by providing them with the most advanced technologies and the experience needed to make headway in translational medicine. EATRIS is a European Research Infrastructure Consortium (ERIC) whose main objective is to advance translational medicine.  Translational research is a highly multidisciplinary and complex undertaking.  One of the greatest challenges in innovation is to understand which steps are necessary and the most appropriate technology and knowledge for taking these steps.

    Més informació "The IMIM becomes part of the European Consortium EATRIS to promote translational medicine"

  • 19/06/2019 - Press release

    Joint Hypermobility Related to Anxiety, Also in Animals

    Researchers from the UAB and the IMIM published in Scientific Reports the first evidence in a non-human species, the domestic dog, of a relation between joint hypermobility and excitability: dogs with more joint mobility and flexibility tend to have more anxiety problems. The relation between collagen laxity and anxiety in humans is widely known, but this relation has never been observed before in other species. A team of researchers led by professors Jaume Fatjó and Antoni Bulbena from the Department of Psychiatry and Legal Medicine at the UAB, the Hospital del Mar Medical Research Institute (IMIM) and the UAB Affinity Foundation Chair in Animals and Health, analysed a set of 13 animal behaviour characteristics and hip joint mobility in a total of 5575 domestic dogs. The results point to an association between hip joint hypermobility and a brain activation linked to emotions in dogs, with similar results as to those observed in people.

    Més informació "Joint Hypermobility Related to Anxiety, Also in Animals"

  • 19/03/2018 - Press release

    Cognitive function in children with Down's syndrome improved by a compound found in green tea

    Dr. Rafael de la Torre, director of the Neurosciences research programme at the Hospital del Mar Medical Research Institute (IMIM), is leading a clinical trial involving a paediatric population, the aim of which is to evaluate the safety and effectiveness of a dietary preparation containing epigallocatechin gallate (EGCG) – a natural compound found in green tea- on improved cognitive development in children, aged 6 to 12, with Down's syndrome, and which will also evaluate its effect on children with Fragile X syndrome. The paediatric clinical trials will take place simultaneously in 5 health centres: Hospital Niño Jesús (Madrid), Instituto Hispalense de Pediatria (Seville), Hospital Universitario Marqués de Valdecilla (Santander), Hospital del Mar ( Barcelona), and Institut Jérome Lejeune (Paris).

    Més informació "Cognitive function in children with Down's syndrome improved by a compound found in green tea"

  • 19/12/2016 - Press release

    Pregnancy Leads to Changes in the Mother’s Brain

    A study directed by researchers from the UAB and IMIM are the first to reveal how pregnancy causes long-lasting alterations in brain structure, probably related to improving the mother’s ability to protect and interact with the child. The research was published in Nature Neuroscience. Pregnancy involves radical hormone surges and biological adaptations, but the effects on the brain are still unknown. In this study a team of researchers compared the structure of the brain of women before and after their first pregnancy. This is the first research to show that pregnancy involves long-lasting changes – at least for two years post-partum – in the morphology of a woman's brain. Using magnetic resonance imaging, the scientists have been able to show that the brains of women who have undergone a first pregnancy present significant reductions in grey matter in regions associated with social cognition.

    Més informació "Pregnancy Leads to Changes in the Mother’s Brain"

  • 07/06/2016 - Press release

    Clinical trial opens new avenues for pharmacological therapy in Down’s syndrome

    A team of scientists led by doctors Rafael de la Torre at Hospital del Mar Medical Research Institute (IMIM) and Mara Dierssen at the Centre for Genomic Regulation (CRG) have shown that epigallocatechin gallate together with a cognitive stimulation protocol, might improve some cognitive domains in individuals with Down’s syndrome.   The results of the phase 2 study will be published on 6th June in the prestigious journal The Lancet Neurology. The findings suggest that participants who had received the treatment had better scores in the visual memory recognition and inhibition tasks, and improvement in adaptive behaviour than those in the control group (placebo and cognitive training). Though not a cure, this is the first time that a treatment has shown some effectiveness in this syndrome, and it opens the door to new research geared towards treating what was believed to be orphan of treatment.

    Més informació "Clinical trial opens new avenues for pharmacological therapy in Down’s syndrome"

  • 26/05/2016 - Events

    Biomarker discovered that measures the risk of cancer in non-smokers

    Researchers from the Hospital del Mar Medical Research Institute (IMIM) have, for the first time, demonstrated that measurements of a tobacco-specific nitrosamine in the hair, NNK, correlate with the real risk of exposure to the carcinogens in tobacco smoke in passive smokers. This substance is a much better biomarker than any of the markers measured up to now for assessing this risk and it has been found in higher concentrations in the hair than any other tobacco-specific carcinogen. The study was conducted in collaboration with researchers at the Catalan Institute of Oncology (ICO) and has been published in the journal Scientific Reports. The smoke passive smokers are exposed to differs from the smoke of smokers. Passive smokers are exposed to a lot of chemicals resulting from the combustion of the cigarette, but in addition, certain substances have gone through various activation reactions, making them carcinogenic.

    Més informació "Biomarker discovered that measures the risk of cancer in non-smokers"

  • 18/01/2016 - Press release

    A novel brain mechanism for nicotine addiction

    Researchers from the Hospital del Mar Medical Research Institute (IMIM) in collaboration with scientists from Pompeu Fabra University, the Pasteur Institute andPierre and Marie Curie University, have discovered a crucial neural mechanism that explains the process of nicotine reward and addiction. Nicotine, the principal psychoactive component of tobacco, is quickly absorbed through the nasal, oral and respiratory membranes and takes 7 seconds to reach the brain where the receptors are located. It is there where it acts on the central nervous system as well as the autonomic nervous system. This almost immediate relationship between the inhalation of the smoke and its effect at a cerebral level is one of the factors contributing to the highly addictive nature of nicotine. This is explained by the fact that the nicotine exerts its psychopharmacological effects by activating receptors that are very abundant in several specific regions of the brain, the nicotinic acetylcholine receptors (nAChR).

    Més informació "A novel brain mechanism for nicotine addiction"

  • 01/12/2015 - General information

    New EMCDDA report explores combined mental health and substance use disorders

    The co-existence of mental illness and psychoactive drug or other substance use problems — otherwise known as ‘comorbidity’ or ‘dual diagnosis’ — is an issue which has been on the radar of the EU drugs agency (EMCDDA) for over a decade. This agency aims to provide objective and reliable information concernint drugs and their consequences.

    Més informació "New EMCDDA report explores combined mental health and substance use disorders"

  • 09/10/2015 - Institutional news

    IMIM receives funding from the IOC to conduct innovative anti-doping research

    In its mission to protect and promote clean athletes, the International Olympic Committee (IOC) is financing and backing seven innovative research projects in the fight against doping, which include a project by Dr Jordi Segura, coordinator of the research group on bioanalysis and analytic services at IMIM. The project is entitled ‘Developments for improving compliance with blood testing, a fundamental but minimally implemented tool in doping control (EASY BLOOD)’ and its purpose is to explore and validate the applicability of the use of new matrices (dried blood spot and capillary sampling) to replace the blood sample collection methods that are currently used to control doping (which are whole blood, plasma and serum). The seven projects funded are from Australia, Spain and the United Kingdom and were selected from among the applications received from throughout the world in the two calls opened by the IOC.

    Més informació "IMIM receives funding from the IOC to conduct innovative anti-doping research"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact